QUOTE AND NEWS
New York Times  Jan 24  Comment 
“Birds of a Feather” at the Met Museum highlights Joseph Cornell’s infatuation with a Cubist masterwork by Juan Gris.
New York Times  Sep 5  Comment 
Mr. Hockney’s new paintings are riveting in their spatial distortions. A born colorist, he’d rather be a Cubist.
NPR  Aug 8  Comment 
Minecraft, one of the most popular video games in the world, is touted for its educational possibilities. But is that potential really accessible to all?
New York Times  Jul 4  Comment 
Mr. Lauder says “there is no issue” with his Cubist trove, but the museum lacks lead donors as it tries to create a suitable home for the collection.
Motley Fool  Aug 7  Comment 
Lonnie Moulder successfully launched Aloxi and then sold MGI Pharma for $3.9 billion in 2008. Now Moulder is building a company that could be even more valuable.
Benzinga  May 7  Comment 
The 2016 Benzinga Fintech Awards is the only event in fintech dedicated to recognizing innovation in financial services and capital markets. Ahead of the May 24th awards show and gala, meet the industry leaders we tapped to determine the most...
FierceBiotech  Mar 6  Comment 
Merck issued its WARN letter today on upcoming cuts at Cubist's Massachusetts operations, outlining plans to shutter its discovery and nondevelopment unit in Lexington, MA, and terminate 128 staffers.
SeekingAlpha  Mar 6  Comment 
FierceBiotech  Mar 5  Comment 
Merck has pulled the plug on Cubist Pharmaceuticals' early R&D operation, cutting 120 jobs in Massachusetts as it integrates its latest big acquisition.
Jutia Group  Jan 22  Comment 
[Business Wire] - Merck , known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck,...




 

Background

Massachusetts-based Cubist Pharmaceuticals, Inc., a biopharmaceutical company formed in 1992, is focused on discovering and developing anti-infective drugs. Its lead product, Cubicin (a first in class lipopeptide), launched in November 2003 in the U.S., is used to treat complicated skin and skin structure infections (cSSSI). Cubist derives substantially all of its revenues from the sale of Cubicin: 94% of 2010 revenues came from US sales of the drug, and an additional 4% came from international sales.

Cubicin

In May, 2006, FDA approved the expanded label of Cubicin for the treatment of bacteremia (a blood infection) and endocarditis (a heart valve infection). Cubicin was also approved in E.U. for cSSSI in Jan 2006 and for bacteremia and endocarditis in August 2007. CBST purchased Cubicin's worldwide development and commercialization rights from Eli Lilly and Company in 1997 in exchange of royalties on product sales. The company has now partnered with Chiron Corporation (now Novartis) to commercialize the drug in the E.U. and some other international markets. Cubist partnered with AstraZeneca in Dec 2006 to develop and commercialize Cubicin in China and other Asian markets. In March 2007, it partnered with Merck & Co., Inc. to develop and commercialize Cubicin in Japan. Now the company has a full complement of partners ready to commercialize Cubicin around the world. Cubist receives royalties on these international sales. In February 2009, Teva filed an ANDA for a generic version of the drug, alleging that US patents 6468967 and 6852689 (expiring September 2019) are unenforceable due to inequitable conduct and that patent RE39071 (expiring June 2016) is invalid. This suit prevents the FDA from approving Teva's ANDA before July 2011 unless a verdict is reached before then.

Other Revenue Sources

  • In July 2006, Cubist terminated its in-house HepeX-B program, an antibody candidate for hepatitis B infection.
  • Through June 30, 2010, Cubist generated service revenues by providing support for Merrem IV in an agreement with AstraZeneca.
  • Cubist holds substantial amounts of cash and short term investments ($909.9 Million as of December 31, 2010) which generate investment income

Product Pipeline

CXA-201

  • Complicated Urinary Tract Infection: Phase 2
  • Complicated Intra Abdominal Infection: Phase 2
  • Nosocomial Pneumonia: Phase 1

CB-183,315

  • Clostridium Difficile-Associated Diarrhea: Phase 2




References

  • www.cubist.com
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki